Albemarle Corp (ALB)

neg -0.25
Today's Range: 49.87 - 50.92 | ALB Avg Daily Volume: 1,470,700
Last Update: 10/13/15 - 4:00 PM EDT
Volume: 917,496
YTD Performance: -16.00%
Open: $50.18
Previous Close: $50.51
52 Week Range: $41.37 - $64.99
Oustanding Shares: 112,201,848
Market Cap: 5,690,877,731
6-Month Chart
TheStreet Ratings Grade for ALB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 6
Moderate Buy 1 1 1 1
Hold 7 7 7 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.07 2.07 2.00 2.13
Latest Dividend: 0.29
Latest Dividend Yield: 2.29%
Dividend Ex-Date: 12/11/15
Price Earnings Ratio: 30.55
Price Earnings Comparisons:
ALB Sector Avg. S&P 500
30.55 32.50 25.41
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.46% -8.21% -2.88%
Revenue -6.50 -0.15 -0.05
Net Income -63.40 -0.50 -0.21
EPS -65.50 -0.65 -0.29
Earnings for ALB:
Revenue 2.45B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.89 $0.96 $3.86 $4.13
Number of Analysts 12 12 11 12
High Estimate $1.03 $1.04 $4.00 $4.41
Low Estimate $0.77 $0.87 $3.69 $3.87
Prior Year $1.14 $0.99 $4.20 $3.86
Growth Rate (Year over Year) -21.64% -3.03% -8.03% 7.05%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Oct 09, 2015 | 7:52 AM EDT
ALB was placed on the Conviction Buy list, according to Goldman Sachs. $63 price target. Better pricing should drive cash flow growth.&...
Jul 29, 2014 | 6:27 AM EDT
ALB was upgraded from Hold to Buy, Topeka Capital said. $91 price target. Company has several positive near-term catalysts.   ...
The consensus of positives is just too cute.
Jan 09, 2014 | 8:07 AM EST
ALB was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $71 price target. See improved growth in Catalysts over the c...
Oct 21, 2013 | 8:01 AM EDT
ALB numbers were bumped into 2014, Jefferies said. Driven by Catalysts and Fine Chemistry segment with opportunity to flex the balance ...
Oct 18, 2013 | 7:50 AM EDT
ALB was downgraded from Buy to Neutral, Sterne Agee said. Estimates also cut, given a slower growth outlook. 
Albemarle looks like a solid low-risk bet with plenty of upside.

Early-Morning Market Look Real Money Pro($)

Let's take a peek at overnight and early-morning price action in the major asset classes.
Apr 01, 2013 | 8:39 AM EDT
ALB earnings estimates through 2014 were reduced based on cautious margin assumptions and slower sales growth, said Jefferies. Price ta...
Jan 24, 2013 | 8:08 AM EST
ALB was downgraded to Neutral from Buy, Citigroup said. $71 price target. Weaker bromine trends. 

Columnist Conversations

Would certainly be taking notes on Hillary's comments regarding drug companies ahead of tomorrow's session...
The Biotech iShares (IBB) dropped sharply last month and then began consolidating in triangle pattern. The dro...
You have to be positioned to be lucky. Well done, Bob.
Sometimes it's better to be lucky than good! As mentioned below, we added the SNDK nov 62.5 calls today on so...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.